BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schulz-Kuhnt A, Greif V, Hildner K, Knipfer L, Döbrönti M, Zirlik S, Fuchs F, Atreya R, Zundler S, López-Posadas R, Neufert C, Ramming A, Kiefer A, Grüneboom A, Strasser E, Wirtz S, Neurath MF, Atreya I. ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure. Front Immunol 2020;11:691. [PMID: 32457736 DOI: 10.3389/fimmu.2020.00691] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Thomsen K, Høiby N, Jensen PØ, Ciofu O, Moser C. Immune Response to Biofilm Growing Pulmonary Pseudomonas aeruginosa Infection. Biomedicines 2022;10:2064. [DOI: 10.3390/biomedicines10092064] [Reference Citation Analysis]
2 Spits H, Mjösberg J. Heterogeneity of type 2 innate lymphoid cells. Nat Rev Immunol 2022. [PMID: 35354980 DOI: 10.1038/s41577-022-00704-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Jin J, Sunusi S, Lu H. Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target. J Int Med Res 2022;50:030006052110531. [DOI: 10.1177/03000605211053156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Bojanowski CM, Lu S, Kolls JK. Mucosal Immunity in Cystic Fibrosis. J I 2021;207:2901-2912. [DOI: 10.4049/jimmunol.2100424] [Reference Citation Analysis]
5 Shen X, Zhang H, Xie H, Chen L, Li S, Zheng J, Chai R, Wang Z, Zang Y, He S. Reduced CCR6+IL-17A+Treg Cells in Blood and CCR6-Dependent Accumulation of IL-17A+Treg Cells in Lungs of Patients With Allergic Asthma. Front Immunol 2021;12:710750. [PMID: 34497608 DOI: 10.3389/fimmu.2021.710750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shastri MD, Allam VSRR, Shukla SD, Jha NK, Paudel KR, Peterson GM, Patel RP, Hansbro PM, Chellappan DK, Dua K. Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases. Life Sci 2021;283:119871. [PMID: 34352260 DOI: 10.1016/j.lfs.2021.119871] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
7 Wirtz S, Schulz-Kuhnt A, Neurath MF, Atreya I. Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time. Front Immunol 2021;12:688879. [PMID: 34177944 DOI: 10.3389/fimmu.2021.688879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Li Y, Wang W, Ying S. Factors affecting the migration of ILC2s in allergic disease. Cell Mol Immunol 2021;18:2069-70. [PMID: 34059792 DOI: 10.1038/s41423-021-00703-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Elashiry M, Elsayed R, Elashiry MM, Rashid MH, Ara R, Arbab AS, Elawady AR, Hamrick M, Liu Y, Zhi W, Lucas R, Vazquez J, Cutler CW. Proteomic Characterization, Biodistribution, and Functional Studies of Immune-Therapeutic Exosomes: Implications for Inflammatory Lung Diseases. Front Immunol 2021;12:636222. [PMID: 33841418 DOI: 10.3389/fimmu.2021.636222] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
10 García M, Kokkinou E, Carrasco García A, Parrot T, Palma Medina LM, Maleki KT, Christ W, Varnaitė R, Filipovic I, Ljunggren HG, Björkström NK, Folkesson E, Rooyackers O, Eriksson LI, Sönnerborg A, Aleman S, Strålin K, Gredmark-Russ S, Klingström J, Mjösberg J; Karolinska KI/K COVID‐19 Study Group. Innate lymphoid cell composition associates with COVID-19 disease severity. Clin Transl Immunology 2020;9:e1224. [PMID: 33343897 DOI: 10.1002/cti2.1224] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]